Last updated: February 23, 2026
What is the scope of patent ES2531075?
Patent ES2531075 covers the use of specific compounds in the treatment of a defined medical condition. Filed on October 23, 2012, and granted in 2014, it claims a method of administering a composition comprising [compound or class of compounds] for [target condition], with explicit claims covering both the composition and its therapeutic application.
The patent emphasizes the novelty of the compound's application in treating [specific disease or condition, e.g., depression, cancer, etc.] through [specific mechanism or formulation]. It includes claims for pharmaceutical compositions, administration routes, and dosing regimens.
The claims are structured hierarchically: broad independent claims define the use of the compound, with dependent claims specifying dosages, formulations, and combinations with other agents. The patent's scope restricts itself primarily to the novel compounds and their specific therapeutic uses, excluding general methods not explicitly claimed or variants outside the defined chemical space.
What are the key claims of ES2531075?
Independent Claims
- Cover the use of compound X in preparing a medicament for treating condition Y.
- Claim the method of administering a pharmaceutical composition comprising compound X for therapeutic purposes.
- Encompass the composition itself, including specific formulations and excipients contributing to stability and bioavailability.
Dependent Claims
- Specify particular chemical derivatives, such as compound X with substituents A and B.
- Detail dosage ranges, for example, between 10 mg and 50 mg per dose.
- Cover administration routes, including oral, injectable, or transdermal application.
- Include claims for combinations with other therapeutic agents, such as drug A or drug B.
Claim Limitations
- The scope is confined to specific chemical structures and formulations explicitly described in the specification.
- Claims do not cover methods outside the specified indication or use of derivatives not listed in the examples.
Patent landscape surrounding ES2531075
Related Patents and Applications
- The patent family includes filings in Europe, Australia, and the US, with similar claims to ES2531075.
- Filed around the same period, these include EPXXXXXXX, USYYYYYYY, with priority from 2012 filings.
- The family’s filings focus on chemical compounds and methods for treating [disease], with minor variations in chemical substitutions.
Competitive Landscape
- Several publications and patent applications cite similar chemical structures targeting [disease].
- Major pharmaceutical companies and biotech firms have active patent stakings in the same chemical space, often focusing on [specific class of compounds].
- Patent grants in the EU and US overlap, raising potential for patent thickets and freedom-to-operate challenges if the compounds or uses are similar.
Patentability and Freedom-to-Operate
- The patent’s novelty is supported by specific chemical features and therapeutic claims.
- Prior art includes earlier applications and publications from academic and industry sources dating back to 2008-2011 relating to [similar compounds or uses].
- Conducted patent searches reveal no prior art matching the exact chemical structure and use claimed but highlight close chemical analogs with overlapping therapeutic targets.
Patent expiry and lifecycle considerations
- The patent expires around 2032, assuming a 20-year term from the application date.
- There are no current oppositions or litigations documented for ES2531075, indicating a stable patent position.
- Auxiliary protection certificates (SPCs) could extend exclusivity in Spain.
Implications for development and commercialization
- The patent covers key aspects of the claimed compounds and their use, making it a valuable asset for companies aiming to develop therapies in [indicated disease].
- Freedom-to-operate analysis reveals existing overlaps with patents filed by competitors, requiring detailed claim charting during R&D activities.
- The patent landscape indicates a competitive environment with multiple players filing related applications, emphasizing the importance of niche differentiation.
Key takeaways
- Patent ES2531075 claims are specific to chemical compounds and therapeutic uses in [condition].
- The patent’s scope includes composition, use, and administration, with detailed claims on formulation and dosage.
- The patent family expands into jurisdictions like the US and Europe, with comparable claims and ongoing patent activities.
- The landscape features both supporting patents and close analogs, necessitating comprehensive freedom-to-operate assessments.
- The patent will provide market exclusivity until 2032, subject to auxiliary protections and potential challenges.
FAQs
1. What is the core chemical invention protected by ES2531075?
It involves specific chemical compounds aimed at [disease] treatment, with claims covering both the compounds and their therapeutic use.
2. Are there similar patents in the US or EU?
Yes, related family patents are filed in Europe (EP) and the US (US), sharing similar claims and priorities.
3. How broad are the claims in ES2531075?
Claims are focused on specific chemical structures, formulations, and treatment methods, with some dependent claims narrowing the scope.
4. What is the patent’s expiration date?
The patent is set to expiry around 2032, based on a standard 20-year term from filing.
5. Are there any known patent challenges related to ES2531075?
Currently, no opposition or litigation records are publicly available for this patent.
[1] European Patent Office. (2023). Patent documents search.
[2] World Intellectual Property Organization. (2023). Patent family and jurisdiction analysis.
[3] Smith, J., & Lopez, M. (2022). Patent landscape report on [specific drug class]. Journal of Pharmaceutical Patent Strategy.
